Borrower record · Q2 2026
Long Grove Pharmaceuticals
As filed by Monroe Capital Income Plus Corp · period end 30 June 2026No sector — one filer, nothing to corroborate
Monroe Capital Income Plus Corp is the only BDC lending to Long Grove Pharmaceuticals: $14.7m across one position at Q2 2026, marked at 101.9 cents. Two of the two positions pay interest in kind, the largest at 400bp.
- Filed fair value
- $14.7m
- 1 funded position
- Aggregate mark
- 101.9c
- covers 50% of positions with a filed cost
- Filed spread
- 800bp
- over SOFR, one floating tranche
- Maturities to
- 2031
- one date, 27 February 2031
- Periods on record
- 3
- Q4 2025 → Q2 2026
How this total is counted
- Every figure above is the sum of 1 funded position filed by Monroe Capital Income Plus Corp, each one cited below.
- Counted from the Q2 2026 filings imported for this build, the latest of them filed 20 August 2026. A schedule filed after that date is not in these figures and will appear when the property is rebuilt.
- 1 filed position carries no positive fair value — unfunded or written off — and is outside every figure above.
Capital structure
First-Lien Senior Secured, on the one position whose seniority a filer disclosed.
Rate structure
Floating, on the one position whose interest type a filer disclosed.
Maturity profile
the one funded position is dated4.7 years to maturity, weighted by fair value across the 1 dated position.
Filed over time
3 periods · aggregate onlyFiled fair value
Aggregate marknot to zero
Q4 2025, Q1 2026, Q2 2026 — every filer reporting the borrower at each period, aggregated. No lender is separated out at any period.
Credit flags
Not in the filings
- No sector, and there cannot be one: the test needs two filers to agree and only one filed a label.
- No filed cost on 50% of positions, which the aggregate mark therefore excludes.
- One floating tranche, so there is no spread range to publish — the single filed spread is above.
- No index floor filed on any tranche.
Sign up for free
Tell me when this changes.
One lender reports Long Grove Pharmaceuticals today. We will email you when a second one does, when Monroe Capital Income Plus Corp's mark moves, or when the position leaves the schedule.
- A second BDC reports this borrower
- The filed mark moves by more than two cents
- A position goes on non-accrual or starts paying in kind
- The borrower drops out of the schedule entirely
Every filing behind this page
1 filer · Q2 2026| Filer | CIK | Form | Period | Filed | Accession |
|---|---|---|---|---|---|
| Monroe Capital Income Plus Corp | 0001742313 | 10-Q | 2026-06-30 | 2026-08-07 | 0001742313-26-000046 |
Related borrowers
Same lender